Titan Pharmaceuticals effects 1-for-20 reverse stock split; CUSIP changes to 888314705

TITAN PHARMACEUTICALS INC

Reverse split at 1-for-20 ratio effective January 8, 2024 at 5:00 p.m. ET.
Stock continues trading on Nasdaq under symbol TTNP with new CUSIP 888314705.
Approved by stockholders at special meeting on December 27, 2023 and by the Board on November 16, 2023.
Continental Stock Transfer & Trust is exchange agent for the reverse split.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TITAN PHARMACEUTICALS INC: Filed Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock, effective January 8, 2024 at 5:00 p.m. Eastern Time (effective 2024-01-08).

Change: charter amendment
Effective: 2024-01-08

Exact text from the filing

On January 8, 2024, Titan Pharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-20 (the “Reverse Split”).

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001829126-24-000082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.